These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33151105)

  • 1. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
    Fischer C; Munks MW; Hill AB; Kroczek RA; Bissinger S; Brand V; Schmittnaegel M; Imhof-Jung S; Hoffmann E; Herting F; Klein C; Knoetgen H
    MAbs; 2020; 12(1):1834818. PubMed ID: 33151105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
    Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
    Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
    Schardt JS; Walseng E; Le K; Yang C; Shah P; Fu Y; Alam K; Kelton CR; Gu Y; Huang F; Lin J; Liu W; Dippel A; Zhang H; Mulgrew K; Pryts S; Chennupati V; Chen HC; Denham J; Chen X; Pradhan P; Wu Y; Hardman C; Zhao C; Kierny M; Song Y; Dovedi SJ; Cemerski S; Mazor Y
    MAbs; 2024; 16(1):2395499. PubMed ID: 39205483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.
    Carey B; DeLay M; Strasser JE; Chalk C; Dudley-McClain K; Milligan GN; Brunner HI; Thornton S; Hirsch R
    Clin Immunol; 2005 Jul; 116(1):65-76. PubMed ID: 15925833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
    Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
    Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
    Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
    Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself.
    Schlingmann TR; Rininsland FH; Bartholomae WC; Kuekrek H; Lehmann PV; Tary-Lehmann M
    Clin Immunol; 2009 Oct; 133(1):45-51. PubMed ID: 19589730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
    Li H; Ou X; Xiong J
    Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
    Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
    Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
    Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
    Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
    Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
    Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.
    Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H
    Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.
    Schmittnaegel M; Levitsky V; Hoffmann E; Georges G; Mundigl O; Klein C; Knoetgen H
    Cancer Immunol Res; 2015 Jul; 3(7):764-76. PubMed ID: 25691327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.